Forward to: R&D Team

Drug Development
Pipeline Workflows

Ten agent workflows for the R&D Team — pipeline tracking, clinical candidate monitoring, drug discovery intelligence, target validation signals, preclinical advancement monitoring, competitive development analysis, biotech partnership opportunities, therapeutic area mapping, IND filing detection, and pipeline dashboard — enabling data-driven R&D decisions powered by comprehensive domain intelligence.

1Competitor Pipeline Monitoring

AI agent monitors pharmaceutical and biotech company domains to track pipeline updates, clinical candidate advancement, therapeutic area pivots, and R&D investment signals across the industry.

1
Track Competitor Pipeline Signals
/products/investors/press/careersOpenPageRank
COMPETITOR PIPELINE INTELLIGENCE — 420 COMPANIES TRACKED ════════════════════════════════════════════════════════ pfizer.com /products: Pipeline updated — 112 programs across 7 therapeutic areas /investors: R&D budget $11.4B — oncology 42% of spend /press: GLP-1 candidate PF-07081532 advancing to Phase 2 SIGNAL: Pfizer entering GLP-1 obesity space — competitive threat modernatx.com /products: mRNA pipeline expanded to 45 programs /investors: R&D efficiency improving — cost per program down 28% /press: Individualized cancer vaccine — Phase 3 enrollment complete SIGNAL: mRNA oncology platform maturing — monitor for licensing regeneron.com /products: Dupixent lifecycle — 3 new indications in Phase 3 /careers: +38% immunology researchers — expansion signal SIGNAL: Dupixent could reach $20B peak sales — line extension strategy

2Biotech Partnership Detection

AI agent identifies biotech companies with promising pipeline candidates by monitoring domain signals — new IND filings, clinical data readouts, and licensing availability indicators.

1
Detect Partnering Opportunities
/products/investors/pressDomain AgeOpenPageRank
BIOTECH PARTNERSHIP OPPORTUNITIES ════════════════════════════════════════════════════════ arcusbio.com — Arcus Biosciences /products: Anti-TIGIT + anti-PD-1 combo — Phase 2 data strong /investors: Cash runway 18 months — may seek partner /press: Multiple tumor types showing response SIGNAL: Ideal licensing target — approach before cash crunch recursion.com — AI drug discovery /products: AI platform — 4 IND-stage candidates /investors: $500M raised — platform validated Domain Age: 3,650 days | PageRank: 6.1 SIGNAL: Platform partnership for our target discovery programs PARTNERSHIP PIPELINE: Biotechs screened: 420 | High-fit targets: 28 Licensing opportunities: 12 active Estimated deal value range: $200M - $2.5B

3Therapeutic Area Intelligence

AI agent maps the competitive landscape within specific therapeutic areas — tracking pipeline density, clinical trial activity, and unmet medical need to inform portfolio strategy.

1
Analyze Therapeutic Area Dynamics
/products/press/aboutIAB Categories
THERAPEUTIC AREA COMPETITIVE MAP — ONCOLOGY ════════════════════════════════════════════════════════ Modality Programs Phase3+ Competition Opportunity ADCs 148 22 Crowded Medium Bispecifics 94 14 Growing High Cell therapy 82 8 Medium High mRNA vaccines 28 4 Low Very High Radiopharm 36 6 Low Very High STRATEGIC RECOMMENDATION: ADCs: Deprioritize — 148 programs in development Radiopharm: High priority — underinvested space with clear unmet need mRNA oncology: Partner with Moderna/BioNTech — don't build

4IND Filing & Preclinical Signals

AI agent detects early-stage pipeline movements by monitoring biotech domain changes that indicate IND preparation, preclinical data generation, and regulatory pre-submission meetings.

1
Detect IND Preparation Signals
/products/careers/pressDomain Age
IND FILING SIGNAL DETECTION ════════════════════════════════════════════════════════ IND SIGNALS DETECTED (LAST 30 DAYS): orbitherapeutics.com /products: Lead candidate ORB-101 — "IND-enabling studies complete" /careers: Hiring clinical operations director /press: Pre-IND meeting with FDA completed SIGNAL: IND filing imminent — novel target in NASH aeriumtherapeutics.com /products: Pipeline page updated — "Phase 1-ready" designation added /careers: Hiring regulatory affairs VP + CRO contracts Domain Age: 1,240 days | PageRank: 3.2 SIGNAL: Early-stage company — potential acquisition at IND stage IND PIPELINE TRACKER: INDs detected (30 days): 14 In our therapeutic areas: 6 Potential licensing targets: 3

5Drug Discovery Technology

AI agent monitors drug discovery technology companies to track AI/ML platforms, high-throughput screening innovations, and computational chemistry advances that could accelerate pipeline programs.

1
Track Discovery Technology Innovation
/products/press/case-studiesOpenPageRank
DRUG DISCOVERY TECHNOLOGY LANDSCAPE ════════════════════════════════════════════════════════ isomorphiclabs.com — Alphabet/DeepMind spinout /products: AI protein structure prediction for drug design /press: Partnerships with Eli Lilly and Novartis announced SIGNAL: Evaluate for structure-based drug design programs schrodinger.com /products: Physics-based computational platform — updated FEP+ /investors: Revenue $230M — pharma collaborations growing 35% /case-studies: 4 IND candidates discovered via platform insilico.com — Insilico Medicine /products: AI-designed molecule ISM001-055 in Phase 2 /press: First AI-discovered drug to reach Phase 2 SIGNAL: Validate AI drug discovery — partner for 2 target programs

6Target Validation Intelligence

AI agent monitors academic research institutions, genetic databases, and peer company target portfolios to identify validated drug targets and emerging biology for pipeline prioritization.

1
Validate Pipeline Targets
/products/press/blogIAB Categories
TARGET VALIDATION INTELLIGENCE ════════════════════════════════════════════════════════ opentargets.org /products: Updated genetic association database — 14,000 targets /blog: Genetically validated targets 2x more likely to succeed SIGNAL: Cross-reference our pipeline targets — 4 have strong genetics ukbiobank.ac.uk /press: 500K participant genomic data — new associations published /about: PCSK9-like validation for 3 emerging targets OUR TARGET VALIDATION STATUS: Targets with genetic evidence: 8 of 14 (57%) Targets with human proof-of-concept: 5 of 14 Undruggable targets with new modalities: 3 enabled by degraders RECOMMENDATION: Prioritize genetically validated targets for Phase 1

7R&D Investment Intelligence

AI agent tracks pharma R&D spending, VC investment in biotech, and deal activity to assess investment trends and identify areas of growing or declining industry interest.

1
Track R&D Investment Trends
/investors/press/aboutOpenPageRank
R&D INVESTMENT LANDSCAPE ════════════════════════════════════════════════════════ TOP 10 PHARMA R&D SPEND (2025): roche.com: $16.1B | jnj.com: $15.2B merck.com: $13.8B | pfizer.com: $11.4B BIOTECH VC INVESTMENT TRENDS: Total 2025: $38B — up 22% from 2024 Oncology: $14B (37%) Neuro: $6.2B (16%) — growing fastest Obesity/metabolic: $4.8B (13%) — GLP-1 driven Rare disease: $3.1B (8%) — declining from peak DEAL ACTIVITY: Licensing deals (2025): 480 — record high Average upfront: $120M — up 35% — valuations rising SIGNAL: Act fast on partnership targets — prices escalating

8Modality Platform Tracking

AI agent monitors emerging drug modality platforms — gene therapy, cell therapy, RNA therapeutics, protein degraders — to track technology maturation and identify platform licensing opportunities.

1
Track Emerging Modalities
/products/press/investorsIAB Categories
EMERGING MODALITY PLATFORM INTELLIGENCE ════════════════════════════════════════════════════════ arvinastherapeutics.com — Protein degraders (PROTACs) /products: 3 clinical-stage PROTACs — Phase 2 data strong /investors: Platform validated — $4B market cap SIGNAL: PROTAC platform licensing available for select targets intelliatx.com — CRISPR gene editing /products: In vivo gene editing — Phase 1 data positive /press: First in vivo CRISPR therapy showing durability at 2 years SIGNAL: Gene editing maturing — evaluate for genetic disease programs alnylam.com — RNAi therapeutics /products: 5 approved RNAi drugs — platform validated /investors: Revenue $2.8B — profitability achieved INSIGHT: RNAi platform proven — 40+ companies now in space

9Pipeline Failure Analysis

AI agent tracks pipeline failures and clinical trial terminations across the industry to identify patterns, inform risk assessment, and avoid investing in targets with high failure rates.

1
Analyze Pipeline Failure Patterns
/investors/press/productsOpenPageRank
PIPELINE FAILURE INTELLIGENCE — 2025 ════════════════════════════════════════════════════════ NOTABLE FAILURES (LAST 90 DAYS): biogen.com — Alzheimer's anti-amyloid #4 failed Phase 3 agenus.com — Anti-CTLA-4 combo missed PFS endpoint sarepta.com — DMD gene therapy — FDA CRL issued FAILURE RATES BY PHASE (2020-2025): Phase 1 → 2: 48% fail Phase 2 → 3: 67% fail (highest attrition) Phase 3 → Approval: 38% fail Overall: ~90% of programs fail OUR RISK ASSESSMENT: Programs at Phase 2: 8 | Expected failures: 5-6 Programs with genetic validation: Lower failure rate (45% vs 67%) INSIGHT: Genetic validation reduces Phase 2 failure rate by 33%

10Pipeline Strategy Dashboard

AI agent synthesizes all pipeline intelligence into an executive dashboard — providing R&D leadership with real-time visibility into competitive positioning, investment trends, and partnership opportunities.

1
Generate Pipeline Intelligence Dashboard
/products/investors/pressOpenPageRankIAB Categories
PIPELINE DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ OUR PIPELINE: Total programs: 32 | Phase 3: 6 | Phase 2: 8 | Phase 1: 12 IND stage: 6 | Peak sales potential: $28B COMPETITIVE LANDSCAPE: Companies tracked: 420 | Pipeline programs monitored: 4,800 Therapeutic overlap threats: 14 programs PARTNERSHIPS: Biotech targets screened: 420 | High-fit: 28 Active licensing discussions: 4 Estimated deal pipeline: $200M - $2.5B
2
Generate Pipeline Report

Pipeline Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Pharma/biotech companies tracked: 420 domains Pipeline programs monitored: 4,800 Partnership targets identified: 28 high-fit IND filings detected (30 days): 14 KEY INSIGHTS GLP-1 competitive intensity increasing with Pfizer entry. Radiopharmaceuticals and mRNA oncology represent highest-opportunity white spaces. AI drug discovery platforms maturing — Insilico first AI-designed drug in Phase 2. Biotech valuations rising — average licensing upfront $120M. PROTAC and gene editing platforms reaching clinical proof-of-concept.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.